Symbols / SANA $3.27 +0.05%
SANA Chart
About
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 873.06M |
| Enterprise Value | 820.53M | Income | -244.17M | Sales | — |
| Book/sh | 0.60 | Cash/sh | 0.52 | Dividend Yield | — |
| Payout | 0.00% | Employees | 142 | IPO | — |
| P/E | — | Forward P/E | -5.35 | PEG | — |
| P/S | — | P/B | 5.43 | P/C | — |
| EV/EBITDA | -4.60 | EV/Sales | — | Quick Ratio | 1.76 |
| Current Ratio | 1.89 | Debt/Eq | 53.62 | LT Debt/Eq | — |
| EPS (ttm) | -0.96 | EPS next Y | -0.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -26.00% |
| ROE | -118.70% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 266.87M |
| Shs Float | 177.45M | Short Float | 36.48% | Short Ratio | 17.91 |
| Short Interest | — | 52W High | 6.55 | 52W Low | 1.26 |
| Beta | 1.96 | Avg Volume | 2.57M | Volume | 354.73K |
| Target Price | $8.43 | Recom | Strong_buy | Prev Close | $3.27 |
| Price | $3.27 | Change | 0.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.43
Mean price target
2. Current target
$3.24
Latest analyst target
3. DCF / Fair value
$-3.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.24
Low
$6.00
High
$12.00
Mean
$8.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2026-01-06 | main | B of A Securities | Buy → Buy | $7 |
| 2025-11-07 | main | Wedbush | Outperform → Outperform | $6 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-10-30 | main | Citizens | Market Outperform → Market Outperform | $8 |
| 2025-09-24 | init | Wedbush | — → Outperform | $5 |
| 2025-06-24 | reit | JMP Securities | Market Outperform → Market Outperform | $5 |
| 2025-04-24 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-18 | up | Citizens Capital Markets | Market Perform → Market Outperform | $5 |
| 2025-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-03-14 | init | Jefferies | — → Buy | $7 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-01-08 | up | TD Cowen | Hold → Buy | — |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-05 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-05 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2024-08-09 | main | Citigroup | Buy → Buy | $15 |
| 2024-08-09 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
- Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient - Fierce Biotech Fri, 13 Mar 2026 14
- This new 'superintelligent co-worker' from Workday takes over 300 office tasks - Stock Titan ue, 17 Mar 2026 13
- H.C. Wainwright reiterates Sana Biotechnology stock buy rating - Investing.com Mon, 16 Mar 2026 11
- Sana Biotechnology, Inc. (SANA): A Bull Case Theory - Yahoo Finance Sat, 28 Feb 2026 08
- Integral Health Asset Management LLC Has $7.10 Million Stock Position in Sana Biotechnology, Inc. $SANA - MarketBeat Sat, 14 Mar 2026 08
- Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips (NASDAQ:SANA) - Seeking Alpha Mon, 19 Jan 2026 08
- Transplanted insulin cells work 14 months without immune drugs in T1D patient - Stock Titan Fri, 13 Mar 2026 13
- Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - Yahoo Finance hu, 08 Jan 2026 08
- Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat hu, 05 Mar 2026 08
- Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data By Investing.com - Investing.com Nigeria Fri, 13 Mar 2026 19
- Year-long diabetes cell transplant works without immune drugs in Sana study - Stock Titan ue, 03 Mar 2026 08
- Sana (SANA) Surges 14.5% Ahead of Business Announcements - Yahoo Finance Fri, 28 Nov 2025 08
- Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes - Stock Titan Wed, 04 Mar 2026 08
- Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance Sun, 30 Nov 2025 08
- Sana Biotechnology stock price target lowered to $7 by H.C. Wainwright - Investing.com Wed, 04 Mar 2026 13
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 13666 | — | — | WYRICK SUSAN D | Officer | — | 2026-03-06 00:00:00 | D | nan |
| 1 | 91666 | — | — | HARR STEVEN D | Chief Executive Officer | — | 2026-03-06 00:00:00 | D | nan |
| 2 | 1525 | — | — | WYRICK SUSAN D | Officer | — | 2026-03-02 00:00:00 | D | nan |
| 3 | 6157 | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2026-01-05 00:00:00 | D | — |
| 4 | 7500 | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2026-01-02 00:00:00 | D | nan |
| 5 | 3400 | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2025-12-12 00:00:00 | D | nan |
| 6 | 20000 | — | — | WYRICK SUSAN D | Chief Financial Officer | — | 2025-12-03 00:00:00 | D | nan |
| 7 | 5628 | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-10-06 00:00:00 | D | — |
| 8 | 7842 | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-07-07 00:00:00 | D | — |
| 9 | 16339 | — | Stock Award(Grant) at price 0.00 per share. | BISHOP HANS EDGAR | Director | — | 2025-04-07 00:00:00 | D | — |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -148.35M | -253.44M | -261.57M | -256.94M |
| TotalUnusualItems | -44.61M | -1.89M | -7.01M | |
| TotalUnusualItemsExcludingGoodwill | -44.61M | -1.89M | -7.01M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -244.17M | -266.76M | -283.25M | -269.48M |
| ReconciledDepreciation | 12.75M | 15.50M | 17.54M | 15.62M |
| EBITDA | -192.96M | -255.33M | -268.58M | -256.94M |
| EBIT | -205.71M | -270.83M | -286.13M | -272.56M |
| NetInterestIncome | 3.85M | 10.47M | 9.94M | 3.76M |
| InterestIncome | 3.85M | 10.47M | 9.94M | 3.76M |
| NormalizedIncome | -199.56M | -264.87M | -276.24M | -269.48M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -244.17M | -266.76M | -283.25M | -269.48M |
| TotalExpenses | 205.71M | 270.83M | 286.13M | 272.56M |
| TotalOperatingIncomeAsReported | -250.32M | -272.72M | -293.14M | -272.56M |
| DilutedAverageShares | 230.89M | 194.54M | 188.34M | 166.43M |
| BasicAverageShares | 230.89M | 194.54M | 188.34M | 166.43M |
| DilutedEPS | -1.16 | -1.46 | -1.43 | -2.14 |
| BasicEPS | -1.16 | -1.46 | -1.43 | -2.14 |
| DilutedNIAvailtoComStockholders | -244.17M | -266.76M | -283.25M | -269.48M |
| NetIncomeCommonStockholders | -244.17M | -266.76M | -283.25M | -269.48M |
| NetIncome | -244.17M | -266.76M | -283.25M | -269.48M |
| NetIncomeIncludingNoncontrollingInterests | -244.17M | -266.76M | -283.25M | -269.48M |
| NetIncomeContinuousOperations | -244.17M | -266.76M | -283.25M | -269.48M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -244.17M | -266.76M | -283.25M | -269.48M |
| OtherIncomeExpense | -42.31M | -6.40M | -7.07M | -674.00K |
| OtherNonOperatingIncomeExpenses | 2.31M | -4.51M | -52.00K | -674.00K |
| SpecialIncomeCharges | -44.61M | -1.89M | -7.01M | |
| ImpairmentOfCapitalAssets | 44.61M | 1.89M | 7.01M | |
| NetNonOperatingInterestIncomeExpense | 3.85M | 10.47M | 9.94M | 3.76M |
| InterestIncomeNonOperating | 3.85M | 10.47M | 9.94M | 3.76M |
| OperatingIncome | -205.71M | -270.83M | -286.13M | -272.56M |
| OperatingExpense | 205.71M | 270.83M | 286.13M | 272.56M |
| ResearchAndDevelopment | 161.41M | 206.79M | 212.83M | 201.00M |
| SellingGeneralAndAdministration | 44.30M | 64.04M | 73.30M | 71.56M |
| GeneralAndAdministrativeExpense | 44.30M | 64.04M | 73.30M | 71.56M |
| OtherGandA | 44.30M | 64.04M | 73.30M | 71.56M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 266.73M | 223.92M | 197.86M | 191.02M |
| ShareIssued | 266.73M | 223.92M | 197.86M | 191.02M |
| TotalDebt | 78.86M | 94.20M | 104.10M | 108.25M |
| TangibleBookValue | -38.94M | 50.68M | 87.68M | 299.49M |
| InvestedCapital | 160.88M | 250.50M | 287.51M | 499.31M |
| WorkingCapital | 69.95M | 115.38M | 149.03M | 332.93M |
| NetTangibleAssets | -38.94M | 50.68M | 87.68M | 299.49M |
| CapitalLeaseObligations | 78.86M | 94.20M | 104.10M | 108.25M |
| CommonStockEquity | 160.88M | 250.50M | 287.51M | 499.31M |
| TotalCapitalization | 160.88M | 250.50M | 287.51M | 499.31M |
| TotalEquityGrossMinorityInterest | 160.88M | 250.50M | 287.51M | 499.31M |
| StockholdersEquity | 160.88M | 250.50M | 287.51M | 499.31M |
| GainsLossesNotAffectingRetainedEarnings | 28.00K | 14.00K | -60.00K | -4.33M |
| OtherEquityAdjustments | 28.00K | 14.00K | -60.00K | -4.33M |
| RetainedEarnings | -1.85B | -1.60B | -1.34B | -1.05B |
| AdditionalPaidInCapital | 2.01B | 1.86B | 1.63B | 1.56B |
| CapitalStock | 27.00K | 22.00K | 20.00K | 19.00K |
| CommonStock | 27.00K | 22.00K | 20.00K | 19.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 256.01M | 250.52M | 277.79M | 323.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 177.28M | 205.08M | 213.31M | 211.90M |
| OtherNonCurrentLiabilities | 113.36M | 123.42M | 122.41M | 116.04M |
| LongTermDebtAndCapitalLeaseObligation | 63.92M | 81.66M | 90.90M | 95.86M |
| LongTermCapitalLeaseObligation | 63.92M | 81.66M | 90.90M | 95.86M |
| CurrentLiabilities | 78.73M | 45.43M | 64.49M | 111.50M |
| OtherCurrentLiabilities | 40.20M | 55.34M | 56.38M | |
| CurrentDebtAndCapitalLeaseObligation | 14.94M | 12.53M | 13.20M | 12.39M |
| CurrentCapitalLeaseObligation | 14.94M | 12.53M | 13.20M | 12.39M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.73M | 11.43M | 19.79M | 21.25M |
| PayablesAndAccruedExpenses | 11.86M | 21.47M | 31.51M | 22.52M |
| CurrentAccruedExpenses | 10.19M | 16.26M | 27.40M | 19.66M |
| Payables | 1.67M | 5.21M | 4.11M | 2.86M |
| AccountsPayable | 1.67M | 5.21M | 4.11M | 2.86M |
| TotalAssets | 416.89M | 501.02M | 565.30M | 822.72M |
| TotalNonCurrentAssets | 268.21M | 340.21M | 351.78M | 378.28M |
| OtherNonCurrentAssets | 3.17M | 5.12M | 6.37M | 9.01M |
| InvestmentsAndAdvances | 0.00 | 10.05M | 195.88M | |
| InvestmentinFinancialAssets | 0.00 | 10.05M | 195.88M | |
| AvailableForSaleSecurities | 10.05M | 195.88M | ||
| GoodwillAndOtherIntangibleAssets | 199.82M | 199.82M | 199.82M | 199.82M |
| OtherIntangibleAssets | 59.20M | 59.20M | 59.20M | 59.20M |
| Goodwill | 140.63M | 140.63M | 140.63M | 140.63M |
| NetPPE | 65.22M | 135.27M | 145.59M | 159.40M |
| AccumulatedDepreciation | -54.76M | -54.17M | -41.77M | -33.98M |
| GrossPPE | 119.97M | 189.44M | 187.36M | 193.38M |
| Leases | 39.06M | 33.34M | 31.36M | 34.43M |
| ConstructionInProgress | 0.00 | 40.34M | 26.33M | 1.71M |
| OtherProperties | 76.78M | 110.92M | 126.55M | 154.33M |
| MachineryFurnitureEquipment | 4.14M | 4.84M | 3.12M | 2.91M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 148.68M | 160.81M | 213.51M | 444.44M |
| OtherCurrentAssets | 6.10M | 4.48M | 4.49M | 14.37M |
| RestrictedCash | 4.20M | 3.83M | 3.83M | 6.10M |
| PrepaidAssets | 7.11M | |||
| CashCashEquivalentsAndShortTermInvestments | 138.38M | 152.50M | 205.19M | 423.96M |
| OtherShortTermInvestments | 66.51M | 24.93M | 71.68M | 247.20M |
| CashAndCashEquivalents | 71.87M | 127.57M | 133.52M | 176.76M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -144.77M | -256.58M | -273.61M | -310.93M |
| RepaymentOfDebt | -347.00K | |||
| IssuanceOfDebt | 126.40M | 188.74M | 27.02M | 0.00 |
| IssuanceOfCapitalStock | 181.00M | 31.65M | 601.00K | 631.75M |
| CapitalExpenditure | -938.00K | -33.43M | -20.03M | -20.88M |
| EndCashPosition | 76.06M | 131.40M | 137.35M | 187.27M |
| BeginningCashPosition | 131.40M | 137.35M | 187.27M | 261.85M |
| ChangesInCash | -55.33M | -5.95M | -49.92M | -74.58M |
| FinancingCashFlow | 128.73M | 199.75M | 31.65M | 4.91M |
| CashFlowFromContinuingFinancingActivities | 128.73M | 199.75M | 31.65M | 4.91M |
| ProceedsFromStockOptionExercised | 2.68M | 11.01M | 4.63M | 4.31M |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 181.00M | 31.65M | 601.00K | 631.75M |
| CommonStockIssuance | 181.00M | 31.65M | 601.00K | 631.75M |
| NetIssuancePaymentsOfDebt | 126.06M | 188.74M | 27.02M | 0.00 |
| NetLongTermDebtIssuance | 126.06M | 188.74M | 27.02M | 0.00 |
| LongTermDebtPayments | -347.00K | |||
| LongTermDebtIssuance | 126.40M | 188.74M | 27.02M | 0.00 |
| InvestingCashFlow | -40.24M | 17.45M | 172.01M | 210.56M |
| CashFlowFromContinuingInvestingActivities | -40.24M | 17.45M | 172.01M | 210.56M |
| NetOtherInvestingChanges | 1.43M | -4.57M | ||
| NetInvestmentPurchaseAndSale | -40.73M | 50.88M | 192.04M | 231.44M |
| SaleOfInvestment | 46.56M | 276.95M | 349.79M | 310.13M |
| PurchaseOfInvestment | -87.29M | -226.06M | -157.74M | -78.69M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -938.00K | -33.43M | -20.03M | -20.88M |
| PurchaseOfPPE | -938.00K | -33.43M | -20.03M | -20.88M |
| OperatingCashFlow | -143.83M | -223.15M | -253.58M | -290.05M |
| CashFlowFromContinuingOperatingActivities | -143.83M | -223.15M | -253.58M | -290.05M |
| ChangeInWorkingCapital | -10.11M | -1.19M | 18.61M | 7.54M |
| ChangeInOtherWorkingCapital | -3.00M | 9.34M | 10.96M | 1.56M |
| ChangeInPayablesAndAccruedExpense | -8.28M | -7.01M | -491.00K | 11.97M |
| ChangeInAccruedExpense | -4.74M | -8.39M | -1.52M | 10.91M |
| ChangeInPayable | -3.54M | 1.38M | 1.03M | 1.06M |
| ChangeInAccountPayable | -3.54M | 1.38M | 1.03M | 1.06M |
| ChangeInPrepaidAssets | 1.17M | -3.51M | 8.14M | -5.99M |
| OtherNonCashItems | 27.63M | -10.28M | -49.03M | -82.08M |
| StockBasedCompensation | 25.46M | 37.68M | 35.53M | 38.34M |
| AssetImpairmentCharge | 44.61M | 1.89M | 7.01M | |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 12.75M | 15.50M | 17.54M | 15.62M |
| DepreciationAndAmortization | 12.75M | 15.50M | 17.54M | 15.62M |
| Depreciation | 12.75M | 15.50M | 17.54M | 15.62M |
| NetIncomeFromContinuingOperations | -244.17M | -266.76M | -283.25M | -269.48M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SANA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|